The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

The purchase by Heartland Food Products comes as sales for the weight loss brand have plummeted, with more consumers turning to GLP-1 medications.

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

Roughly one out of every two people who start taking semaglutide (Wegovy; Novo Nordisk) to lose weight will stop taking the medication within a year, according to a large population-based study out of ...

Obesity is linked to accelerated aging and early death and is typically defined by body mass index, a measure of weight and ...

Over the last six years, three GLP-1 drugs have been approved for children aged 10 and older with type 2 diabetes. | Over the ...

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc.

As the new Chief Wellness Amassador at Noom, a weight loss platform, Rebel Wilson is endorsing their GLP-1 'microdosing' campaign.

Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported ...

The research, published in the journal Diabetes, Obesity and Metabolism, suggests that the injectable GLP-1 drugs may make food taste sweeter and saltier for some, which could be a good thing for ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass ...